AnaptysBio, Inc. (ANAB)
NASDAQ: ANAB · Real-Time Price · USD
53.36
-1.68 (-3.05%)
At close: Jul 31, 2026, 4:00 PM EDT
54.00
+0.64 (1.20%)
After-hours: Jul 31, 2026, 7:34 PM EDT
AnaptysBio Balance Sheet
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Assets
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Equivalents | 248.47 | 238.2 | 123.08 | 35.97 | 71.31 | 495.73 |
Short-Term Investments | 37.99 | 73.44 | 262.29 | 354.94 | 369.93 | 52.37 |
Cash & Short-Term Investments | 286.46 | 311.64 | 385.37 | 390.9 | 441.24 | 548.1 |
Cash Growth | -15.73% | -19.13% | -1.42% | -11.41% | -19.50% | 39.23% |
Other Receivables | 25.75 | 33.85 | 40.77 | 6.85 | 1.42 | 0.88 |
Total Trade Receivables | 25.75 | 33.85 | 40.77 | 6.85 | 1.42 | 0.88 |
Other Current Assets | 3.91 | 4.76 | 5.74 | 9.08 | 4.55 | 4.9 |
Total Current Assets | 316.11 | 350.25 | 431.88 | 406.84 | 447.21 | 553.88 |
Net Property, Plant & Equipment | 13.32 | 13.89 | 16.23 | 18.27 | 19.99 | 21.84 |
Long-Term Investments | - | - | 35.47 | 27.03 | 142.94 | 67.1 |
Other Long-Term Assets | 0.26 | 0.26 | 0.26 | 0.26 | 0.26 | 0.26 |
Total Assets | 329.68 | 364.4 | 483.83 | 452.39 | 610.38 | 643.07 |
Liabilities
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Accounts Payable | 7.52 | 3.87 | 4 | 4.7 | 2.78 | 1.74 |
Accrued Expenses | 32.07 | 32.67 | 39.5 | 30.97 | 21.63 | 12.85 |
Current Portion of Leases | 2.12 | 2.08 | 1.93 | 1.78 | 1.64 | 1.51 |
Total Current Liabilities | 41.7 | 38.63 | 45.43 | 37.44 | 26.05 | 16.1 |
Long-Term Leases | 11.49 | 12.03 | 14.11 | 16.04 | 17.81 | 19.45 |
Other Long-Term Liabilities | 263.74 | 276.53 | 353.43 | 310.81 | 304.41 | 251.09 |
Total Long-Term Liabilities | 275.24 | 288.56 | 367.54 | 326.84 | 322.23 | 270.54 |
Total Liabilities | 316.94 | 327.19 | 412.97 | 364.29 | 348.28 | 286.64 |
Shareholders' Equity
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Common Stock | 0.03 | 0.03 | 0.03 | 0.03 | 0.03 | 0.03 |
Additional Paid-in Capital | 838.31 | 809.77 | 829.86 | 702.97 | 717.8 | 678.58 |
Accumulated Other Comprehensive Income | -0.15 | -0.02 | 0.31 | -0.8 | -5.25 | -0.42 |
Retained Earnings | - | - | -759.33 | -614.1 | -450.48 | -321.75 |
Shareholders' Equity | 838.19 | 809.77 | 70.87 | 88.1 | 262.1 | 356.43 |
Total Liabilities & Equity | 329.68 | 364.4 | 483.83 | 452.39 | 610.38 | 643.07 |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Total Debt | 13.61 | 14.11 | 16.04 | 17.81 | 19.45 | 20.96 |
Net Cash (Debt) | 272.84 | 297.53 | 369.34 | 373.09 | 421.79 | 527.14 |
Net Cash Growth | -15.88% | -19.44% | -1.01% | -11.55% | -19.98% | 34.03% |
Net Cash Per Share | 9.26 | 10.35 | 13.01 | 13.86 | 14.98 | 19.22 |
Book Value | 838.19 | 809.77 | 70.87 | 88.1 | 262.1 | 356.43 |
Book Value Per Share | 28.45 | 28.16 | 2.50 | 3.27 | 9.31 | 12.99 |
Tangible Book Value | 838.19 | 809.77 | 70.87 | 88.1 | 262.1 | 356.43 |
Tangible Book Value Per Share | 28.45 | 28.16 | 2.50 | 3.27 | 9.31 | 12.99 |